Financial SustainabilityKodiak Sciences has an annualized cash burn of $230 million, with only 0.5 years of cash left.
Market ChallengesKOD's tarcocimab is in GLOW2 ph.III for DR with data expected, but there is an expectation of limited market opportunity due to low VEGF use in NPDR patients without DME.
Safety ConcernsOpen questions on safety and visual outcomes remain for vamikibart, as full data from the BARDENAS or ALLUVIUM trials have not been presented.